Information provision for patients by breast cancer teams about the side-effects of hormone treatments.

The choice of adjuvant hormone treatments in post-menopausal women with breast cancer increasingly includes anastrozole as an alternative to tamoxifen. Clearly there may be overlapping side-effects, but other important differences may have serious implications for health and quality of life. Patients consequently require information regarding the side-effects of recommended treatments and their comparisons. This study evaluates the extent of information provision about the side-effects of adjuvant anastrozole and tamoxifen by respective breast cancer professionals within 16 different breast care teams in the United Kingdom (UK). The study used interviews with individual members of breast cancer multidisciplinary teams (surgeons, oncologists and breast care nurses) from 11 cancer centres and 3 district general hospitals, to examine the information they give to patients relating to the side-effects of tamoxifen and anastrozole. The results show that vasomotor symptoms were the most frequently mentioned side-effect for both treatments. All teams, in large part addressed the adverse effects of both treatments (endometrial cancer and thrombo-embolic events for tamoxifen and anastrozole-associated loss of bone density). There was variation between the different professionals as to how frequently side-effects were mentioned. The greatest discrepancies occurred between the information given by team members and that included in patient information leaflets. In some cases, important information pertaining to side-effects was omitted from leaflets. This study suggests the need to standardise information-provision nationally in the UK and within breast cancer teams regarding the evidence-based side-effects of tamoxifen and anastrozole.

[1]  J. Costantino,et al.  Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. , 1998, Statistics in medicine.

[2]  M. Dowsett,et al.  Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. , 2004, European journal of cancer.

[3]  L. Fallowfield,et al.  Are members of multidisciplinary teams in breast cancer aware of each other's informational roles? , 2001, Quality in health care : QHC.

[4]  L. Siu,et al.  Impact of the media and the internet on oncology: survey of cancer patients and oncologists in Canada. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Saul,et al.  Information needs of patients with cancer: results from a large study in UK cancer centres , 2001, British Journal of Cancer.

[6]  D. Cameron,et al.  Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). , 2004, Breast.

[7]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[8]  J. Cuzick,et al.  Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Fallowfield,et al.  Participation of patients in decisions about treatment for cancer , 2001, BMJ : British Medical Journal.

[10]  The NICE guidance on supportive and palliative care--implications for oncology teams. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[11]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Paganini-Hill,et al.  Eye problems in breast cancer patients treated with tamoxifen , 2000, Breast Cancer Research and Treatment.

[13]  L. Fallowfield,et al.  Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial , 2005 .

[14]  M. Baum.  Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group) , 2002 .

[15]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.

[16]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[18]  R. Day.  Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial , 2001 .

[19]  S. Duffy.  Gynecological adverse events including hysterectomy with anastrozole tamoxifen: Data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial , 2005 .

[20]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .